You are here: Industry Insights > Rivastigmine

News List

Luye Pharma Grants Zambon Exclusive Commercialization Rights to Its Innovative Alzheimer's Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Switzerland prnasia
November 11, 2021
Luye Pharma Group (Luye Pharma) today announced that its subsidiary Luye Pharma Switzerland AG has entered into an agreement with Zambon Switzerland (Zambon)...
Luye Pharma's Innovative Alzheimer's Disease Therapy Rivastigmine Multi-Day Transdermal Patch Now Eligible for Marketing Authorization in Several EU Countries prnasia
May 24, 2021
Luye Pharma Group today announced the successful completion of the Decentralised Registration Procedures (DCPs) for its Rivastigmine Multi-Day Transdermal Patch (Rivastigmine MD).
Breckenridge Announces Final Approval of ANDA for Rivastigmine Transdermal System americanpharmaceuticalreview
December 30, 2019
Breckenridge Pharmaceutical announced the U.S. Food and Drug Administration (FDA) has granted final approval for its Abbreviated New Drug Application for ...
Donepezil Ups Risk for Hospital Admission for Rhabdomyolysis drugs
September 17, 2019
Initiating donepezil to manage symptoms of Alzheimer disease or other dementias is associated with a higher risk for 30-day admission to the hospital with rhabdomyolysis compared with initiating rivastigmine or galantamine...
Amneal Announces Approval of Rivastigmine Transdermal System americanpharmaceuticalreview
January 15, 2019
Amneal Pharmaceuticals has received FDA approval for a generic version of Exelon Patch (Rivastigmine Transdermal System), 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours.....